Facebook
Twitter
Telegram
Report an ErrorAnavex Life Sciences Corp. Balance Sheet 2011-2024 | AVXL
Annual Balance Sheet Anavex Life Sciences Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | -22.2 M | -22.9 M | -27.4 M | -9.19 M | -15.2 M | -1.35 M | -134 K | 288 K | 733 K |
Long Term Debt |
- | - | - | - | - | - | - | - | 332 | 5.72 M | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | 332 | 5.72 M | 904 K | - | - |
Total Current Liabilities |
- | - | - | - | 5.04 M | 3.88 M | 3.58 M | 3.19 M | 2.66 M | 1.44 M | 1.95 M | - | - |
Total Liabilities |
12.5 M | 10.2 M | 10.8 M | 7.31 M | 5.04 M | 3.88 M | 3.58 M | 3.19 M | 2.66 M | 7.16 M | 2.86 M | 2.89 M | 1.35 M |
Deferred Revenue |
- | - | - | - | - | - | - | 70.5 K | 71.6 K | - | - | - | - |
Retained Earnings |
-293 M | -246 M | -198 M | -160 M | -133 M | -109 M | -91.5 M | -78 M | -63.3 M | -52.6 M | -41.2 M | -37.5 M | -29.2 M |
Total Assets |
154 M | 153 M | 162 M | 34.5 M | 25.3 M | 24.4 M | 27.8 M | 9.5 M | 15.5 M | 7.35 M | 393 K | 13.2 K | 203 K |
Cash and Cash Equivalents |
151 M | 149 M | 152 M | 29.2 M | 22.2 M | 22.9 M | 27.4 M | 9.19 M | 15.3 M | 7.26 M | 345 K | 11.4 K | 135 K |
Book Value |
142 M | 142 M | 151 M | 27.2 M | 20.3 M | 20.5 M | 24.3 M | 6.31 M | 12.8 M | 193 K | -2.46 M | -2.88 M | -1.14 M |
Total Shareholders Equity |
142 M | 142 M | 151 M | 27.2 M | 20.3 M | 22.3 M | 24.3 M | 6.31 M | 12.8 M | 193 K | -2.46 M | -2.88 M | -1.14 M |
All numbers in USD currency
Quarterly Balance Sheet Anavex Life Sciences Corp.
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 345 | 337 | 265 | 332 | 332 | 332 | - | 5.72 M | 1.09 K | 1.01 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
9.56 M | 12.5 M | 12.5 M | 11.1 M | 14 M | 13.2 M | 10.2 M | - | - | - | 10.8 M | 9.27 M | - | - | 7.31 M | - | - | - | 5.04 M | - | - | - | - | - | - | - | 3.58 M | - | - | - | 3.19 M | 2.17 M | 2.43 M | 2.53 M | 2.66 M | 2.66 M | 2.66 M | 6.58 M | 7.16 M | 7.16 M | 7.16 M | 1.82 M | 2.86 M | 2.86 M | 2.86 M | 3.41 M | 2.89 M | 2.89 M | 2.89 M | 2.57 M | 1.35 M | 1.35 M | 1.35 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-312 M | -302 M | -293 M | -283 M | -272 M | -259 M | -246 M | -231 M | -219 M | -208 M | -198 M | -186 M | -198 M | -168 M | -160 M | -160 M | -160 M | -140 M | -133 M | -133 M | -133 M | -116 M | -107 M | -109 M | -109 M | -95.5 M | -91.5 M | -91.5 M | -91.5 M | -81.2 M | -78 M | -78 M | -78 M | -67.2 M | -63.3 M | -63.3 M | -63.3 M | - | -51.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
145 M | 148 M | 154 M | 158 M | 159 M | 148 M | 153 M | 160 M | 160 M | 157 M | 162 M | 166 M | 162 M | 54.3 M | 34.5 M | 34.5 M | 34.5 M | 31.4 M | 25.3 M | 25.3 M | 25.3 M | 22.1 M | 26.2 M | 24.4 M | 24.4 M | 28.3 M | 27.8 M | 27.8 M | 27.8 M | 21.4 M | 9.5 M | 9.5 M | 9.5 M | 14 M | 15.5 M | 15.5 M | 15.5 M | 7.05 M | 7.35 M | 7.35 M | 7.35 M | 151 K | 393 K | 393 K | 393 K | 79.9 K | 13.2 K | 13.2 K | 13.2 K | 84.6 K | 203 K | 203 K | 203 K |
Cash and Cash Equivalents |
139 M | 144 M | 151 M | 155 M | 153 M | 144 M | 149 M | 153 M | 153 M | 151 M | 152 M | 158 M | 152 M | 47.4 M | 29.2 M | 29.2 M | 47.4 M | 27.5 M | 22.2 M | 22.2 M | 22.2 M | 20.7 M | 22.9 M | 25.8 M | 25.7 M | 28 M | 27.4 M | 24.8 M | 23.4 M | 21.2 M | 9.19 M | 9.19 M | 21.2 M | 13.9 M | 15.3 M | 15.3 M | 13.9 M | 6.98 M | 7.26 M | 7.26 M | 6.98 M | 95.9 K | 345 K | 345 K | 95.9 K | 79.8 K | 11.4 K | 11.4 K | 79.8 K | 9.08 K | 135 K | 135 K | 9.08 K |
Book Value |
135 M | 136 M | 142 M | 147 M | 145 M | 135 M | 142 M | 160 M | 160 M | 157 M | 151 M | 157 M | 162 M | 54.3 M | 27.2 M | 34.5 M | 34.5 M | 31.4 M | 20.3 M | 25.3 M | 25.3 M | 22.1 M | 26.2 M | 24.4 M | 24.4 M | 28.3 M | 24.3 M | 27.8 M | 27.8 M | 21.4 M | 6.31 M | 7.33 M | 7.07 M | 11.5 M | 12.8 M | 12.8 M | 12.8 M | 473 K | 193 K | 193 K | 193 K | -1.67 M | -2.46 M | -2.46 M | -2.46 M | -3.33 M | -2.88 M | -2.88 M | -2.88 M | -2.48 M | -1.14 M | -1.14 M | -1.14 M |
Total Shareholders Equity |
135 M | 136 M | 142 M | 147 M | 145 M | 135 M | 142 M | 151 M | 152 M | 146 M | 151 M | 157 M | 75.8 M | 46.3 M | 27.2 M | 46.3 M | 46.3 M | 26 M | 20.3 M | 26 M | 26 M | 19.5 M | 22.3 M | 17.2 M | 17.2 M | 25.5 M | 25.9 M | 24.3 M | 25.5 M | 19.2 M | 6.31 M | 6.31 M | 6.31 M | 11.5 M | 12.8 M | 12.8 M | 12.8 M | 473 K | 193 K | 193 K | 193 K | -1.67 M | -2.46 M | -2.46 M | -2.46 M | -3.33 M | -2.88 M | -2.88 M | -2.88 M | -2.48 M | -1.14 M | -1.14 M | -1.14 M |
All numbers in USD currency